Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.52 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10047141 | 0.99 | ADORA2A (0.51) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL10047134 | 0.93 | ADORA2A (0.51) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL10072757 | 0.92 | ADORA2A (0.48) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL612224 | 0.87 | ADORA2A (0.44) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL611076 | 0.86 | ADORA2A (0.43) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL611764 | 0.85 | ADORA2A (0.44) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL16705270 | 0.85 | CDK1 (0.46) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL611356 | 0.82 | CDK1 (0.43) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL5401987 | 0.81 | ADORA2A (0.65) | ADORA2ATMIGD3ADORA1ADORA2BCDK1 | |
| SCHEMBL431825 | 0.80 | CDK1 (0.61) | CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895734-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8884008-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-11 | — | — | US | disclosed |
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-10-30 | — | — | US | disclosed |
| US-8859766-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-10-14 | — | — | US | disclosed |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-8680253-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2012-02-16 | — | — | US | disclosed |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | ADORA2A 1651/4885TMIGD3 910/4885ADORA1 1032/4885 |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | ADORA2A 1651/4885TMIGD3 910/4885ADORA1 1032/4885 |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | ADORA2A 1651/4885TMIGD3 910/4885ADORA1 1032/4885 |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | ADORA2A 1651/4885TMIGD3 910/4885ADORA1 1032/4885 |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | ADORA2A 1651/4885TMIGD3 910/4885ADORA1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.